DSP-2230
From Infogalactic: the planetary knowledge core
Jump to: navigation, search
DSP-2230 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
See also
References
| Opioids |
|
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anilines | |||||||||||||||||
| NSAIDs |
|
||||||||||||||||
| Cannabinoids | |||||||||||||||||
| Channelergics |
|
||||||||||||||||
| Myorelaxants | |||||||||||||||||
| Others | |||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://infogalactic.com/w/index.php?title=DSP-2230&oldid=712094319"
